SCHEMBL3908386

SCHEMBL3908386

CCCn1[nH]c(=O)c2cc(NS(=O)(=O)c3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.50
HTR6 P50406 3/20 0.48
HIF1A Q16665 1/20 0.48
DGAT1 O75907 1/20 0.46
NR3C1 P04150 1/20 0.46
PGR P06401 1/20 0.46
AR P10275 1/20 0.46
ESR2 Q92731 1/20 0.46
TOP2A P11388 1/20 0.45
TSHR P16473 1/20 0.44
PTPN2 P17706 3/20 0.44
PTPN1 P18031 3/20 0.44
PTPN5 P54829 3/20 0.44
HSPD1 P10809 2/20 0.44
HSPE1 P61604 2/20 0.44
FFAR1 O14842 1/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917148 0.88 NR3C1 (0.48) HSD17B2HTR6HIF1ANR3C1PGR
SCHEMBL3909496 0.87 HSD17B2 (0.49) HSD17B2HTR6HIF1ANR3C1PGR
SCHEMBL1807440 0.86 NR3C1 (0.51) HSD17B2HTR6HIF1ANR3C1PGR
SCHEMBL3994973 0.80 DGAT1 (0.56) DGAT1GAA
SCHEMBL1809464 0.79 PTGDR2 (0.49) HTR6TSHR
SCHEMBL3911015 0.79 PPARG (0.44) HSD17B2NR3C1PGRARESR2
SCHEMBL4359570 0.79 NR3C1 (0.48) HSD17B2HTR6HIF1ANR3C1PGR
SCHEMBL27678794 0.77 HDAC1 (0.50) HSD17B2HTR6HIF1ANR3C1PGR
SCHEMBL1806371 0.76 CCR4 (0.49) PGR
SCHEMBL1811589 0.74 TRIM24 (0.50) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 HSD17B2 6/4885HTR6 2847/4885HIF1A 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.